Nicholas Blondin, MD
Associate ProfessorCards
About
Research
Publications
2024
NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS
Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.Peer-Reviewed Original ResearchGrade 2 lesionsTumor gradeDeuterium metabolic imagingMetabolic imagingNon-enhancing tumor regionsBrain tumorsTumor-to-brain contrastTumour-specific valuesActive tumor tissueImage contrastVOI-based analysisGrade 4Evaluate disease progressionTesla MRI scannerFDG-PETGrade 3Lesion gradeTumor tissuesDisease progressionDisease stageOral administrationTumorObservational studyNormal brainContrast enhancementKS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Perry J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelson T, Owen S, Mason W, Drappatz J, Blondin N, de Groot J. KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology 2024, 26: v5-v5. PMCID: PMC11485821, DOI: 10.1093/neuonc/noae144.013.Peer-Reviewed Original Research500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Weller M, Berry D, Blondin N, Buxton M, Colman H, de Groot J, de la Fuente M, Ducray F, Ellingson B, Gordon G, Lassman A, Lee E, Lim M, Mellinghoff I, Perry J, Sulman E, Yung W, Wen P, Wick A, Cloughesy T. 500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Annals Of Oncology 2024, 35: s426-s427. DOI: 10.1016/j.annonc.2024.08.569.Peer-Reviewed Original ResearchBSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE
Kandigian S, Chande S, Dolezal D, Tang T, Wang D, Arnal-Estapé A, Cheok S, McGuone D, Liu Y, Goldberg S, Blondin N, Chiang V, Nguyen D. BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE. Neuro-Oncology Advances 2024, 6: i7-i7. PMCID: PMC11296776, DOI: 10.1093/noajnl/vdae090.020.Peer-Reviewed Original ResearchNon-small cell lung cancerLeptomeningeal diseaseCentral nervous systemLeptomeningeal metastasesParenchymal metastasesCerebrospinal fluidTumor cellsTyrosine kinase inhibitor treatmentCell lung cancerKinase inhibitor treatmentCerebrospinal fluid of patientsCell linesCerebral lateral ventriclesIntra-arterial injectionTGF-b signalingIn vivo passageIntraparenchymal diseaseMechanisms of progressionTumor microenvironmentMultiplex immunofluorescenceAggressive treatmentLeptomeningeal infiltrationPerivascular invasionIntraparenchymal metastasesMurine modelReal-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.
Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.Peer-Reviewed Original ResearchNon-small cell lung cancerDiagnosis of LMNational Comprehensive Cancer NetworkLeptomeningeal metastasesTumor cell assayPositive CTCsCerebrospinal fluidData cutoffOverall survivalNeurological symptomsAssessment of circulating tumor DNASensitivity of tumor cell detectionCTC assayManagement of leptomeningeal metastasisTime of data cutoffDiagnosis of leptomeningeal metastasisAssociated with longer survivalMedian overall survivalOmmaya reservoir placementEnumeration of circulating tumor cellsNegative cytology resultsCell lung cancerEffective treatment optionProgressive neurological symptomsInitiation of treatmentEvaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
de Groot J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelsen T, Owen S, Mason W, Drappatz J, Blondin N, Perry J. Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Journal Of Clinical Oncology 2024, 42: 2005-2005. DOI: 10.1200/jco.2024.42.16_suppl.2005.Peer-Reviewed Original ResearchOverall survivalHazard ratioBayesian predictive powerRandomized to CStage 1OS hazard ratioPromoter methylation statusSample sizeRecurrent glioblastomaIncreased OSEfficacy goalsInter-strand DNA crosslinksTargeted agentsRegistration trialsMultiple therapiesDNA double-strand breaksSubtypesDNA-targeting agentsPatient subtypesDouble-strand breaksGlioblastoma subtypesMethylation statusNDMRD
2023
SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Sweed N, Dugan M, Kesari S. SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY. Neuro-Oncology Advances 2023, 5: iii20-iii20. PMCID: PMC10402348, DOI: 10.1093/noajnl/vdad070.077.Peer-Reviewed Original ResearchNon-small cell lung cancerUpper GI cancerHER2-negative primary tumorsAnti-HER2 therapyBreast cancer patientsLeptomeningeal metastasesNegative primary tumorsPrimary tumorHER2 amplificationGI cancersCancer patientsNSCLC patientsBreast cancerHER2-positive primary tumorsUpper GI cancer patientsCSF tumor cellsGI cancer patientsPositive primary tumorsCell lung cancerDiscretion of physiciansIT trastuzumabLM tumorsHER2 positivityNSCLC cancerLM patientsAn expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.Peer-Reviewed Original ResearchConceptsMedian overall survivalProgression-free survivalOverall survivalRecurrent glioblastomaAdverse eventsTherapy groupMedian progression-free survivalDevice-related adverse eventsSafety/feasibilitySerious adverse eventsFurther prospective studiesConcurrent therapyInvestigator's discretionStandard chemotherapyProspective studyTRIAL REGISTRATIONPatientsMonthsTreatmentHome-use deviceGlioblastomaWeeksSurvivalTotalGroupThe clinical and genomic features of seizures in meningiomas
Dincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.Peer-Reviewed Original ResearchPeritumoral brain edemaPostoperative seizuresBrain invasionSubtotal resectionBrain edemaLarge residual tumor volumeCentral nervous system tumorsCommon central nervous system tumorPersistent postoperative seizuresResidual tumor volumeHistory of seizuresHigh tumor gradeNervous system tumorsQuality of lifePreoperative seizuresAtypical histologyMost patientsSurgical resectionCortical hyperexcitabilityUncontrolled seizuresAggressive featuresSeizure activityEpileptogenic focusCortical irritationRisk factorsImaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original Research
Clinical Trials
Current Trials
A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE
HIC ID2000037963RolePrincipal InvestigatorPrimary Completion Date06/30/2025Recruiting ParticipantsA Phase III Trial of Pre-Operative Stereotactic Radiosurgery (SRS) Versus Post-Operative SRS for Brain Metastases
HIC ID2000036148RoleSub InvestigatorPrimary Completion Date01/31/2027Recruiting ParticipantsGenderBothAge18+ yearsA Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
HIC ID2000035675RoleSub InvestigatorPrimary Completion Date01/31/2024Recruiting ParticipantsGenderBothAge18+ yearsAn Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
HIC ID2000032308RoleSub InvestigatorPrimary Completion Date06/30/2024Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Nicholas A. Blondin, MD, is a Yale Medicine neurologist who specializes in treating benign (noncancerous) and malignant (cancerous) brain tumors, brain and spine metastasis, and neurological symptoms of cancer such as seizures, cognitive impairment, headaches, gait disturbance, and weakness. He cares for patients at Smilow Cancer Hospital in New Haven and the Smilow Cancer Hospital Cancer Care Center in Trumbull.
“I love developing a strong doctor-patient relationship with my patients,” Dr. Blondin says. “I believe that a strong, trusting relationship is critical for me to help patients achieve their treatment goals and have the best possible quality of life.”
Dr. Blondin believes in “shared decision making,” a process he uses to create a treatment plan that will be best for each patient. “With a difficult diagnosis, I am open and honest but also work to provide hope that treatment will be effective,” Dr. Blondin says. “I let patients know that I will always be there for them, and I will support them in all phases of treatment.”
Together with a team of doctors at Smilow, he is able to help more patients achieve better outcomes. “In neuro-oncology, I rely on additional specialists such as neurosurgeons, radiation oncologists, pathologist, and neuro-radiologists in order to provide the best care for my patients,” he says.
Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center and is an assistant professor of clinical neurology at Yale School of Medicine.
Clinical Specialties
Neuro-Oncology; Neurology
Fact Sheets
Atypical Teratoid/Rhabdoid Tumors
Learn More on Yale MedicineNeuroblastoma
Learn More on Yale MedicineBrain Tumors
Learn More on Yale MedicineEpendymoma
Learn More on Yale Medicine
Board Certifications
Neuro-Oncology
- Certification Organization
- United Council for Neurologic Subspecialties
- Latest Certification Date
- 2022
- Original Certification Date
- 2015
Yale Medicine News
News & Links
News
Get In Touch
Contacts
Appointment Number
Clinical Inquiry Number
Clinic Fax Number
Mailing Address
Yale Cancer Center
Smilow Trumbull Care Center, 5520 Park Avenue
Trumbull, CT 06611
United States
Administrative Support
Locations
Neuro-Oncology
Academic Office
Lippard Laboratory of Clinical Investigation (LLCI)
15 York Street
New Haven, CT 06510
Business Office
203.737.7084Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.